nadunolimab,nab-paclitaxel,gemcitabine
cantargia
['biomarker', 'gemcitabine', 'nadunolimab', 'paclitaxel', 'cantargia']
cantargia: aacr annual meeting (2023) - tumor il1rap levels and reduction in serum biomarkers correlate with response in pdac patients treated with nadunolimab, an anti-il1rap monoclonal antibody, in combination with gemcitabine and nab-paclitaxel 
Computers are useless. They can only give you answers.